BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 28829761)

  • 1. Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer.
    Aleskandarany MA; Sonbul S; Surridge R; Mukherjee A; Caldas C; Diez-Rodriguez M; Ashankyty I; Albrahim KI; Elmouna AM; Aneja R; Martin SG; Ellis IO; Green AR; Rakha EA
    Br J Cancer; 2017 Oct; 117(8):1176-1184. PubMed ID: 28829761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
    Aleskandarany MA; Abduljabbar R; Ashankyty I; Elmouna A; Jerjees D; Ali S; Buluwela L; Diez-Rodriguez M; Caldas C; Green AR; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2016 Sep; 159(2):215-27. PubMed ID: 27514395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer.
    Kariri YA; Joseph C; Kurozumi S; Toss MS; Alsaleem M; Raafat S; Mongan NP; Aleskandarany MA; Green AR; Rakha EA
    Breast Cancer Res Treat; 2020 Jan; 179(2):349-357. PubMed ID: 31679074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts.
    Aleskandarany MA; Agarwal D; Negm OH; Ball G; Elmouna A; Ashankyty I; Nuglozeh E; Fazaludeen MF; Diez-Rodriguez M; Nolan CC; Tighe PJ; Green AR; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2016 Feb; 156(1):9-20. PubMed ID: 26907764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression profiling of RTL1 in human breast cancer tissues and cell lines.
    Mahmoudi AR; Ghods R; Madjd Z; Abolhasani M; Saeednejad Zanjani L; Safaei M; Balaei Goli L; Vafaei S; Katouzian L; Soltanghoraei H; Shekarabi M; Zarnani AH
    Exp Mol Pathol; 2021 Aug; 121():104654. PubMed ID: 34087231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical significance of cyclin B1 (CCNB1) in invasive breast cancer with emphasis on its contribution to lymphovascular invasion development.
    Aljohani AI; Toss MS; Green AR; Rakha EA
    Breast Cancer Res Treat; 2023 Apr; 198(3):423-435. PubMed ID: 36418517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.
    El Ansari R; Alfarsi L; Craze ML; Masisi BK; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2020 May; 181(1):1-12. PubMed ID: 32200487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
    Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
    Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.
    Joseph C; Macnamara O; Craze M; Russell R; Provenzano E; Nolan CC; Diez-Rodriguez M; Sonbul SN; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Mukherjee A
    Br J Cancer; 2018 Apr; 118(8):1142-1151. PubMed ID: 29588513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
    Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
    Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A key genomic subtype associated with lymphovascular invasion in invasive breast cancer.
    Kurozumi S; Joseph C; Sonbul S; Alsaeed S; Kariri Y; Aljohani A; Raafat S; Alsaleem M; Ogden A; Johnston SJ; Aleskandarany MA; Fujii T; Shirabe K; Caldas C; Ashankyty I; Dalton L; Ellis IO; Desmedt C; Green AR; Mongan NP; Rakha EA
    Br J Cancer; 2019 Jun; 120(12):1129-1136. PubMed ID: 31114020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type.
    Weigelt B; Geyer FC; Natrajan R; Lopez-Garcia MA; Ahmad AS; Savage K; Kreike B; Reis-Filho JS
    J Pathol; 2010 Jan; 220(1):45-57. PubMed ID: 19877120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of therapeutic targets and prognostic biomarkers from the hnRNP family in invasive breast carcinoma.
    Zhou J; Guo Y; Huo Z; Xing Y; Fang J; Ma G; Han Q; Wang M; Xu Q
    Aging (Albany NY); 2021 Jan; 13(3):4503-4521. PubMed ID: 33495416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
    Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
    Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of PRL-3, Snail, Cytokeratin and Vimentin expression in epithelial mesenchymal transition in breast carcinoma.
    Patel NA; Patel PS; Vora HH
    Breast Dis; 2015; 35(2):113-27. PubMed ID: 25547164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.
    Shubbar E; Helou K; Kovács A; Nemes S; Hajizadeh S; Enerbäck C; Einbeigi Z
    BMC Cancer; 2013 Feb; 13():47. PubMed ID: 23374458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy.
    Jia H; Jia W; Yang Y; Li S; Feng H; Liu J; Rao N; Jin L; Wu J; Gu R; Zhu L; Chen K; Deng H; Zeng Y; Liu Q; Song E; Su F
    World J Surg Oncol; 2014 Sep; 12():289. PubMed ID: 25241216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer.
    Kariri YA; Alsaleem M; Joseph C; Alsaeed S; Aljohani A; Shiino S; Mohammed OJ; Toss MS; Green AR; Rakha EA
    Breast Cancer Res Treat; 2021 Jan; 185(2):293-305. PubMed ID: 33073304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancer.
    Chen JQ; Litton J; Xiao L; Zhang HZ; Warneke CL; Wu Y; Shen X; Wu S; Sahin A; Katz R; Bondy M; Hortobagyi G; Berinstein NL; Murray JL; Radvanyi L
    Horm Cancer; 2010 Feb; 1(1):21-33. PubMed ID: 21761348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.